查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179911

2022-2029 年全球計量霧化吸入器市場

Global Metered Dose Inhaler Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

預計在預測期內（2022 年至 2029 年），計量吸入器的全球市場規模將顯著增長。

定量吸入器 (MDI) 是一種加壓吸入器，使用推進劑噴霧來輸送藥物。 它被患有呼吸系統疾病如哮喘、慢性阻塞性肺病（COPD）、慢性支氣管炎和肺氣腫的人廣泛使用。

市場動態

由於哮喘和慢性阻塞性肺病等呼吸系統疾病患者的增加、先進技術的興起、研發投入的增加以及對藥物研發投入的增加等因素，計量吸入器市場正在增長新興國家的醫療保健基礎設施，有望擴大。

呼吸驅動吸入器的採用率不斷提高，研發投資不斷增加，預計將推動市場增長。

計量吸入器市場的驅動力是技術不斷進步、計量吸入器需求增加、研發投資激增、哮喘、慢性阻塞性肺病、慢性支氣管炎等慢性呼吸道疾病增多、新興技術改進新藥以及該國醫療基礎設施的進步都是因素。 據世界衛生組織稱，慢性阻塞性肺病 (COPD) 影響著全世界近 2 億人。 目前，政府增加用於治療慢性病的資金正在推動市場的增長。 例如，在歐盟，慢性阻塞性肺病的直接成本約佔醫療保健總成本的 6%，佔呼吸系統疾病總成本的近 56%。

技術進步正在推動計量吸入器的採用。 呼吸系統疾病的增加，公眾對先進呼吸設備的認識提高，例如用於呼吸系統疾病的支氣管擴張吸入器比傳統治療具有更多有益特性，以及政府和私營公司增加醫療保健支出。這種增長可能會導致基礎設施投資增加，推動計量吸入器市場。

各種新產品的發布和研究正在為市場的增長做出貢獻。 例如，2022 年 5 月 17 日，Teva Pharmaceutical Industries Ltd. 旗下公司 Teva Pharmaceuticals 宣布其新制定的短效 BETA-激動劑 (SABA) 臨床閾值強調了 SABA 在美國哮喘患者中的實際應用States. 基於研究結果和數字吸入器 ProAir Digihaler（硫酸沙丁胺醇）吸入粉劑的潛力。

與計量吸入器相關的環境或副作用預計會阻礙市場增長。

但是，計量吸入器會釋放對環境有害的氣體，即氟利昂 (CFC) 和氫氟烷 (HFA) 生物危害性推進劑，對計量吸入器市場的增長產生負面影響。

關於批准這些計量吸入器的嚴格規則和條例以及與支氣管擴張劑相關的震顫、心悸、神經緊張和肌肉痙攣等不良事件阻礙了市場增長。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID 病例的增加，各種研究和臨床試驗被推遲，計量霧化器市場因 COVID 遭受了巨大損失。 主要製造商已經啟動了各種研究和臨床試驗。 全球正在發生多項舉措、產品發布、合作和合併，推動了市場的增長。 例如，2021 年 12 月 17 日，安進公司宣布阿斯利康和安進公司的 Tezspire（tezepelumab-ekko）獲得美國食品藥品監督管理局（FDA）的批准，用於 12 歲兒童和成人嚴重哮喘患者的附加維持治療和更老。宣布它是

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第4章市場動態

  • 市場影響因素
    • 司機
      • 增加呼吸驅動吸入器的滲透率
      • 研發費用增加
      • 不斷進步的技術進步
    • 約束因素
      • 與定量吸入藥物相關的副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按產品類型

  • 手動加壓吸入器
  • 呼吸加壓吸入器

第8章藥物

  • 腎上腺皮質類固醇
    • 通風孔
    • 維克羅文
    • Azuma 外套
    • 班殼
    • 庫巴爾
    • 布地奈德
    • 健美操
  • 支氣管擴張劑
    • 長效支氣管擴張劑
      • Cerebent（沙美特羅）
      • Foredyl（福莫特羅）
    • 短效支氣管擴張劑
      • 文託林
      • 最大空氣
      • 普羅文泰
      • Zopenex
      • 專業空氣
      • 阿爾彭特
  • 組合藥物（皮質類固醇和支氣管擴張劑）
    • 信必可
    • 亞代爾

第9章應用

  • 慢性阻塞性肺疾病 (COPD)
  • 支氣管哮喘
  • 肺氣腫
  • 慢性支氣管炎
  • 支氣管痙攣
  • 其他

第 10 章（按銷售渠道）

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • F. Hoffmann-La Roche
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • AstraZeneca
  • GSK plc
  • Pfizer Inc.
  • Amgen Inc.
  • Novartis AG
  • Boehringer Ingelheim GmbH
  • Cipla Inc.
  • Merck & Co. Inc.
  • Teva Pharmaceutical Industries Ltd.

第14章 計量吸入器的全球市場-DataM

簡介目錄
Product Code: DMMD52

Market Overview

The global metered dose inhaler market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

A metered-dose inhaler (MDI) is a pressurized inhaler that delivers medication using a propellant spray. It is widely useful for people with respiratory disorders like asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, and emphysema.

Market Dynamics

The market for metered dose inhalers is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.

The rising adoption of breathing-actuated inhalers and increasing investment in research and development are expected to drive the market's growth.

The metered dose inhaler market is driven by rising advancements in technology, an increase in demand for metered dose inhalers, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.

Technological advances have resulted in increasing metered dose inhaler adoption. The rising number of respiratory disorders, and increasing awareness among people about advanced respiratory devices like bronchodilators inhalers and bronchodilators inhalers for respiratory disorders, which have beneficial features over the traditional treatment methods and rising healthcare expenditure by governments and the private sector, could lead to higher infrastructure investments and drive the metered dose inhaler market.

Various novel product launches and research studies contribute to the market's growth. For instance, in May 17, 2022, Teva Pharmaceuticals, a Teva Pharmaceutical Industries Ltd. affiliate, announced its novel study findings based on the usage of short-acting beta agonist (SABA)'s novel established clinical thresholds that highlight real-world use of SABA in asthma patients in the U.S. and the potential for a digital inhaler, ProAir Digihaler (albuterol sulfate) inhalation powder.

The environmental or side effects associated with metered-dose inhalers are expected to hamper the market's growth.

However, metered dose inhalers release environmentally-hazardous gases, namely chlorofluorocarbon (CFC) and hydrofluoroalkanes (HFA) biohazard nature propellants, which negatively impact the metered dose inhalers market's growth.

Stringent rules and regulations for approval of these metered dose inhalers and adverse events such as trembling, palpitations, nervous tension, muscle cramps, and others linked with bronchodilators hinder the market growth.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The metered dose inhaler market has experienced huge losses due to COVID as various research, and clinical trials got postponed due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen's Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.

Segment Analysis

The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The bronchodilators segment is the highest market holder in the global metered dose inhaler market. The global metered dose inhaler market is segmented based on medications in corticosteroids, bronchodilators, and combinations (corticosteroids & bronchodilators). The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.

These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA), who experienced asthma exacerbations.

Geographical Analysis

North America holds the largest market share in the global metered dose inhaler market.

North America dominates the global metered dose inhaler market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults in the United States suffered from chronic obstructive pulmonary disease (COPD) in 2020. And 25 million had asthma.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of medications of metered dose inhalers in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the metered dose inhaler market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in September 21, 2020, Teva Respiratory, LLC., Teva Pharmaceutical Industries Ltd. affiliate announced the launch of two digital maintenance inhalers AirDuo Digihaler (salmeterol and fluticasone propionate) and ArmonAir Digihaler (fluticasone propionate) inhalation powder, for patients with asthma. AirDuo Digihaler is a prescription medicine used to prevent wheezing and control asthma symptoms in people 12 years and older.

Competitive Landscape

The metered dose inhaler market is highly competitive with local and global companies' presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Pfizer Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim GmbH, Cipla Inc., Merck & Co. Inc., Teva Pharmaceutical Industries Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in April 9, 2020, Cipla Limited announced receiving final approval from the United States Food and Drug Administration (US FDA) for its inhalation aerosol, Albuterol Sulfate 90mcg (base)/actuation's abbreviated new drug application (ANDA). This is Cipla's first AB-rated generic therapeutic similar version of Proventil HFA Inhalation Aerosol of Merck Sharp & Dohme Corp's. It is utilized for treating acute episodes of bronchospasm or asthmatic symptoms prevention.

Novartis AG.

Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Proventil HFA: Proventil HFA (albuterol sulfate) inhalation aerosol is used for reversible obstructive airway disease, like asthma, and to treat or prevent bronchospasm in four years and older patients.

Key Development: In March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. With this acquisition, Sandoz acquired Coalesce's significant capabilities that can help build on its existing respiratory medicines portfolio.

The global metered dose inhaler market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising adoption of breathing actuated inhaler
      • 4.1.1.2. Increasing research and development expenditure
      • 4.1.1.3. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the metered dose inhaler drugs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Manually-Actuated Pressurized Inhalers *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Breath-Actuated Pressurized Inhalers

8. By Medications

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 8.1.2. Market Attractiveness Index, By Medications
  • 8.2. Corticosteroids*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 8.2.3. Flovent
    • 8.2.4. Beclovent
    • 8.2.5. Azmacort
    • 8.2.6. Vanceril
    • 8.2.7. Qvar
    • 8.2.8. Budesonide
    • 8.2.9. Aerobid
  • 8.3. Bronchodilators
    • 8.3.1. Long-Acting Bronchodilators
      • 8.3.1.1. Serevent (salmeterol)
      • 8.3.1.2. Foradil (formoterol)
    • 8.3.2. Short-Acting Bronchodilators
      • 8.3.2.1. Ventolin
      • 8.3.2.2. Maxair
      • 8.3.2.3. Proventil
      • 8.3.2.4. Xopenex
      • 8.3.2.5. ProAir
      • 8.3.2.6. Alupent
  • 8.4. Combination (Corticosteroid & Bronchodilators)
    • 8.4.1. Symbicort
    • 8.4.2. Advair

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Chronic Obstructive Pulmonary Disease (COPD) *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Asthma
  • 9.4. Emphysema
  • 9.5. Chronic Bronchitis
  • 9.6. Bronchospasm
  • 9.7. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. F. Hoffmann-La Roche *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. AstraZeneca
  • 13.3. GSK plc
  • 13.4. Pfizer Inc.
  • 13.5. Amgen Inc.
  • 13.6. Novartis AG
  • 13.7. Boehringer Ingelheim GmbH
  • 13.8. Cipla Inc.
  • 13.9. Merck & Co. Inc.
  • 13.10. Teva Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

14. Global Metered Dose Inhaler Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Application
  • 14.3. Contact Us